T helper (Th)-cytokines in the urine of patients with primary glomerulonephritis treated with immunosuppressive drugs: Can they predict outcome?

Cytokine

Volumn 76, Issue 2, 2015, Pages 260-269

  Kalavrizioti, Dimitra ^a   Gerolymos, Miltiadis ^a   Rodi, Maria ^b   Kalliakmani, Pantelitsa ^a   Provatopoulou, Simela ^a   Eleftheriadis, Theodoros ^c   Mouzaki, Athanasia ^b   Goumenos, Dimitrios S ^a  

^a UNIVERSITY HOSPITAL OF PATRAS   (Greece)

^b UNIVERSITY OF PATRAS   (Greece)

^c UNIVERSITY OF THESSALY   (Greece)

Author keywords

Focal segmental glomerulosclerosis; IgA nephropathy; MCP 1 chemokine; Membranous nephropathy; Minimal change disease; Th cytokines

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN A; MONOCYTE CHEMOTACTIC PROTEIN 1; PREDNISOLONE; STEROID; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; CCL2 PROTEIN, HUMAN; CYTOKINE; GAMMA INTERFERON; IL10 PROTEIN, HUMAN; IL17A PROTEIN, HUMAN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6;

ADULT; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DETERIORATION; FEMALE; FOCAL GLOMERULOSCLEROSIS; FOLLOW UP; HELPER CELL; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY FUNCTION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEMBRANOUS GLOMERULONEPHRITIS; MINIMAL CHANGE GLOMERULONEPHRITIS; PRIORITY JOURNAL; PROTEINURIA; REMISSION; TREATMENT OUTCOME; URINALYSIS; URINARY EXCRETION; AGED; GLOMERULONEPHRITIS; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; IMMUNOLOGY; KIDNEY; MIDDLE AGED; PATHOPHYSIOLOGY; PROGNOSIS; URINE;

ADULT; AGED; CHEMOKINE CCL2; CYTOKINES; FEMALE; GLOMERULONEPHRITIS; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-17; INTERLEUKIN-2; INTERLEUKIN-4; INTERLEUKIN-6; KIDNEY; MALE; MIDDLE AGED; PROGNOSIS; PROTEINURIA;

EID: 84943815470     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2015.08.002     Document Type: Article

References (41)

1. Chadban S.J., Atkins R.C. Glomerulonephritis. Lancet 2005, 365(9473):1797-1806.
2. Nangaku M., Couser W.G. Mechanisms of immune-deposit formation and the mediation of immune renal injury. Clin Exp Nephrol 2005, 9(3):183-191.
3. Couser W.G. Basic and translational concepts of immune-mediated glomerular diseases. JASN 2012, 23(3):381-399.
4. Ortega L.M., Fornoni A. Role of cytokines in the pathogenesis of acute and chronic kidney disease, glomerulonephritis, and end-stage kidney disease. Int J Interferon Cytokine Mediator Res 2010, 2(1):49-62.
5. Viedt C., Dechend R., Fei J., Hänsch G.M., Kreuzer J., Orth S.R. MCP-1 induces inflammatory activation of human tubular epithelial cells: involvement of the transcription factors, nuclear factor-κB and activating protein-1. JASN 2002, 13(6):1534-1547.
6. Liu B.C., Zhang L., Lv L.L., Wang Y.L., Liu D.G., Zhang X.L. Application of antibody array technology in the analysis of urinary cytokine profiles in patients with chronic kidney disease. Am J Nephrol 2006, 26(5):483-490.
7. Wan Y.Y. Multi-tasking of helper T cells. Immunology 2010, 130(2):166-171.
8. Thongboonkerd V., Malasit P. Renal and urinary proteomics: current applications and challenges. Proteomics 2005, 5(4):1033-1042.
9. [accessed 18.02.15]. http://www.hkupp.org/Urine%20collectiion%20Documents.htm.
10. Chung A.C., Lan H.Y. Chemokines in renal injury. J Am Soc Nephrol 2011, 22(5):802-809.
11. Kalliakmani P., Koutroulia E., Sotsiou F., Vlachojannis J.G., Goumenos D.S. Benefit and cost from the long-term use of cyclosporine - a in idiopathic membranous nephropathy. Nephrology (Carlton) 2010, 15(8):762-767.
12. Kalliakmani P., Nakopoulou L., Tsakas S., Gerolymos M., Papasotiriou M., Goumenos D.S. Urinary interleukin-6 (IL-6) and transforming growth factor (TGF-β) levels in corticosteroid treated patients with IgA nephropathy. Clin Nephrol 2011, 76(2):144-150.
13. Stangou M., Alexopoulos E., Papagianni A., Pantzaki A., Bantis C., Dovas S., et al. Urinary levels of epidermal growth factor, interleukin-6 and monocyte chemoattractant protein-1 may act as predictor markers of renal function outcome in immunoglobulin A nephropathy. Nephrology (Carlton) 2009, 14(6):613-620.
14. Stangou M., Papagianni A., Bantis C., Moisiadis D., Kasimatis S., Spartalis M., et al. Up-regulation of urinary markers predict outcome in IgA nephropathy but their predictive value is influenced by treatment with steroids and azathioprine. Clin Nephrol 2013, 80:203-210.
15. Abujam B., Cheekatla S.S., Aggarwal A. Urinary CXCL-10/IP-10 and MCP-1 as markers to assess activity of lupus nephritis. Lupus 2013, 22:614-623.
16. Mezzano S.A., Droguett M.A., Burgos M.E., Ardiles L.G., Aros C.A., Caorsi I., et al. Overexpression of chemokines, fibrogenic cytokines, and myofibroblasts in human membranous nephropathy. Kidney Int 2000, 57(1):147-158.
17. Honkanen E., Teppo A.M., Törnroth T., Groop P.H., Grönhagen-Riska C. Urinary transforming growth factor-beta 1 in membranous glomerulonephritis. Nephrol Dial Transplant 1997, 12(12):2562-2568.
18. Wasilewska A., Zoch-Zwierz W., Taranta-Janusz K., Kołodziejczyk Z. Urinary monocyte chemoattractant protein-1 excretion in children with glomerular proteinuria. Scand J Urol Nephrol 2011, 45(1):52-59.
19. Huang Z., Wen Q., Zhou S.F., Yu X.Q. Differential chemokine expression in tubular cells in response to urinary proteins from patients with nephrotic syndrome. Cytokine 2008, 42(2):222-233.
20. Woroniecki R.P., Shatat I.F., Supe K., Du Z., Kaskel F.J. Urinary cytokines and steroid responsiveness in idiopathic nephrotic syndrome of childhood. Am J Nephrol 2008, 28(1):83-90.
21. Kim M.J., Tam F.W. Urinary monocyte chemoattractant protein-1 in renal disease. Clin Chim Acta 2011, 412(23-24):2022-2030.
22. Camilla R., Brachemi S., Pichette V., Cartier P., Laforest-Renald A., MacRae T., et al. Urinary monocyte chemotactic protein 1: marker of renal function decline in diabetic and nondiabetic proteinuric renal disease. J Nephrol 2001, 24(1):60-67.
23. Segerer S., Nelson P.J., Schlondorff D. Chemokines, chemokine receptors, and renal disease: from basic science to pathophysiologic and therapeutic studies. J Am Soc Nephrol 2000, 11:152-176.
24. Galliera E., Corsi M.M., Bonecchi R., Locati M., Mantovani A. Chemokines as pharmacological targets. Mini Rev Med Chem 2008, 8:638-646.
25. Chung A.C., Huang X.R., Zhou L., Heuchel R., Lai K.N., Lan H.Y. Disruption of the Smad7 gene promotes renal fibrosis and inflammation in unilateral ureteral obstruction (UUO) in mice. Nephrol Dial Transplant 2009, 24:1443-1454.
26. Huang X.R., Chung A.C., Zhou L., Wang X.J., Lan H.Y. Latent TGF-beta1 protects against crescentic glomerulonephritis. J Am Soc Nephrol 2008, 19:233-242.
27. Border W.A., Noble N.A. Transforming growth factor β in tissue fibrosis. New Engl J Med 1994, 331:1286-1292.
28. Goumenos D.S., Tsakas S., El Nahas A.M., Alexandri S., Oldroyd S., Kalliakmani P., et al. Transforming growth factor-β(1) in the kidney and urine of patients with glomerular disease and proteinuria. Nephrol Dial Transplant 2002, 17(12):2145-2152.
29. Miossec P., Korn T., Kuchroo V.K. Interleukin-17 and type 17 helper T cells. New Engl J Med 2009, 361(9):888-898.
30. Kitching A.R., Holdsworth S.R. The emergence of Th17 cells as effectors of renal injury. J Am Soc Nephrol 2011, 22(2):235-238.
31. Van Kooten C., Boonstra J.G., Paape M.E., Fossiez F., Banchereau J., Lebecque S., et al. Interleukin-17 activates human renal epithelial cells in vitro and is expressed during renal allograft rejection. J Am Soc Nephrol 1998, 9:1526-1534.
32. Paust H.J., Turner J.E., Steinmetz O.M., Peters A., Heymann F., Holscher C., et al. The IL-23/Th17 axis contributes to renal injury in experimental glomerulonephritis. J Am Soc Nephrol 2009, 20:969-979.
33. Iyoda M., Shibata T., Kawaguchi M., Hizawa N., Yamaoka T., Kokubu F., et al. IL-17A and IL-17F stimulate chemokines via MAPK pathways (ERK1/2 and p38 but not JNK) in mouse cultured mesangial cells: synergy with TNF-a and IL-1b. Am J Physiol Renal Physiol 2009, 298:F779-F787.
34. Tipping P.G., Holdsworth S.R. T cells in crescentic glomerulonephritis. J Am Soc Nephrol 2006, 17:1253-1263.
35. De Paiva V.N., Monteiro R.M., Marques Vde P., Cenedeze M.A., Teixeira Vde P., Dos Reis M.A. Critical involvement of Th1-related cytokines in renal injuries induced by ischemia and reperfusion. Int Immunopharmacol 2009, 9:668-672.
36. Holdsworth S.R., Kitching A.R., Tipping P.G. Th1 and Th2 T helper subsets affect patterns of injury and outcomes in glomerulonephritis. Kidney Int 1999, 55(4):1198-1216.
37. Henri S., Chevillard C., Mergani A., Paris P., Gaudart J., Camilla C., et al. Cytokine regulation of periportal fibrosis in humans infected with Schistosoma mansoni: IFN-gamma is associated with protection against fibrosis and TNF-alpha with aggravation of disease. J Immunol 2002, 169:929-936.
38. Kitching A.R., Tipping P.G., Huang X.R., Mutch D.A., Holdsworth S.R. Interleukin-4 and interleukin-10 attenuate established crescentic glomerulonephritis in mice. Kidney Int 1997, 52:52-59.
39. Shao D.D., Suresh R., Vakil V., Gomer R.H., Pilling D. Pivotal advance. Th-1 cytokines inhibit, and Th-2 cytokines promote fibrocyte differentiation. J Leukoc Biol 2008, 83(6):1323-1333.
40. Kisseleva T., Brenner D.A. Mechanisms of fibrogenesis. Exp Biol Med (Maywood) 2008, 233(2):109-122.
41. Sato M., Muragaki Y., Saika S., Roberts A.B., Ooshima A. Targeted disruption of TGF-beta1/Smad3 signaling protects against renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction. J Clin Invest 2003, 112(10):1486-1494.